NeoGenomics, Inc. (NASDAQ:NEO) – Stock analysts at William Blair cut their Q2 2018 earnings per share (EPS) estimates for NeoGenomics in a report released on Thursday, June 21st. William Blair analyst A. Murphy now expects that the medical research company will post earnings of $0.02 per share for the quarter, down from their prior forecast of $0.03. William Blair also issued estimates for NeoGenomics’ Q4 2018 earnings at $0.05 EPS.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, May 1st. The medical research company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01. The firm had revenue of $63.40 million during the quarter, compared to the consensus estimate of $62.31 million. NeoGenomics had a positive return on equity of 3.19% and a negative net margin of 0.86%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.03 earnings per share.
Several other analysts also recently weighed in on the company. BTIG Research restated a “buy” rating and issued a $15.00 price objective on shares of NeoGenomics in a report on Thursday. ValuEngine upgraded NeoGenomics from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 17th. First Analysis downgraded NeoGenomics from an “overweight” rating to an “equal weight” rating and set a $11.00 price objective for the company. in a report on Wednesday, May 2nd. BidaskClub upgraded NeoGenomics from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 28th. Finally, Canaccord Genuity lifted their price objective on NeoGenomics from $23.00 to $24.00 in a report on Tuesday, March 13th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. NeoGenomics currently has an average rating of “Buy” and a consensus target price of $17.86.
NEO stock opened at $14.05 on Monday. The company has a quick ratio of 1.85, a current ratio of 2.03 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $1.12 billion, a P/E ratio of 234.17, a PEG ratio of 6.63 and a beta of 0.48. NeoGenomics has a 1-year low of $7.08 and a 1-year high of $14.18.
In other NeoGenomics news, insider Steven C. Jones sold 160,312 shares of NeoGenomics stock in a transaction dated Tuesday, June 19th. The stock was sold at an average price of $13.32, for a total value of $2,135,355.84. Following the transaction, the insider now owns 241,815 shares in the company, valued at $3,220,975.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steven A. Ross sold 81,999 shares of NeoGenomics stock in a transaction dated Thursday, May 10th. The shares were sold at an average price of $10.78, for a total value of $883,949.22. Following the completion of the transaction, the insider now owns 4,500 shares in the company, valued at approximately $48,510. The disclosure for this sale can be found here. Insiders sold 606,078 shares of company stock worth $7,263,081 in the last quarter. 12.20% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. Quantitative Systematic Strategies LLC purchased a new stake in shares of NeoGenomics during the first quarter worth about $100,000. Campbell & CO Investment Adviser LLC grew its stake in shares of NeoGenomics by 64.3% during the first quarter. Campbell & CO Investment Adviser LLC now owns 17,127 shares of the medical research company’s stock worth $140,000 after acquiring an additional 6,700 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in shares of NeoGenomics during the first quarter worth about $152,000. Teacher Retirement System of Texas purchased a new stake in shares of NeoGenomics during the fourth quarter worth about $182,000. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of NeoGenomics during the fourth quarter worth about $235,000. Institutional investors and hedge funds own 83.26% of the company’s stock.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.